We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




Inappropriate Sepsis Therapy Leads to Reduced Survival

By HospiMedica International staff writers
Posted on 20 Nov 2009
A new study claims that those patients experiencing septic shock who receive inappropriate therapy could suffer a five-fold reduction in survival. More...


Researchers at the University of Manitoba (Winnipeg, MB, Canada), King Saud Bin Abdulaziz University for Health Sciences (Riyadh, Saudi Arabia), and other institutions retrospectively reviewed 5,715 patients in three countries with septic shock to determine the appropriateness of initial antimicrobial therapy, clinical infection site, and relevant pathogens. The study results showed that inappropriate initial antimicrobial therapy occurred in 20% of patients, with overall survival at 43.7%; survival after appropriate and inappropriate initial therapy, respectively, was 52% and 10.3%. Furthermore, the decrease in survival with inappropriate initial therapy ranged from a 2.3-fold decrease for pneumococcal infection to a 17.6-fold decrease with primary bacteremia. After adjustment for acute physiology and chronic health evaluation II score, comorbidities, hospital site, and other potential risk factors, the inappropriateness of initial antimicrobial therapy remained most highly associated with risk of death. The study was published in the November 2009 issue of Chest.

"Inappropriate initial antimicrobial therapy for septic shock occurs in about 20% of patients and is associated with a fivefold reduction in survival,” concluded lead author Anand Kumar, M.D., of the section of critical care medicine at the University of Manitoba, and colleagues. "Efforts to increase the frequency of the appropriateness of initial antimicrobial therapy must be central to efforts to reduce the mortality of patients with septic shock.”

A problem in the adequate management of septic patients is the delay in administering therapy after sepsis has been recognized. Published studies have demonstrated that for every hour of delay in the administration of appropriate antibiotic therapy there is an associated 7% rise in mortality. A large international collaboration has been established to educate people about sepsis and to improve patient outcomes with sepsis, entitled the Surviving Sepsis Campaign. The campaign has published an evidence-based review of management strategies for severe sepsis, with the aim of eventually publishing a complete set of guidelines.

Related Links:
University of Manitoba

King Saud Bin Abdulaziz University for Health Sciences

Surviving Sepsis Campaign



Gold Member
12-Channel ECG
CM1200B
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Pressure Guidewire
SavvyWire
Mobile X-Ray System
K4W
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Surgical Techniques

view channel
Image: The fiber in the brain implant is less than half a millimeter thick (Photo courtesy of Peter Aagaard Brixen)

Brain Implant Records Neural Signals and Delivers Precise Medication

Neurological diseases such as epilepsy involve complex interactions across multiple layers of the brain, yet current implants can typically stimulate or record activity from only a single point.... Read more

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.